Thank you, Mr. Chair.
I would like to share my time with Mr. Woodworth, if I may.
I would like to go back to report 1. We've talked a lot about developing a pan-Canadian antimicrobial resistance strategy, but this report is about a little bit more than that. It also speaks to surveillance of antimicrobial resistance and use, and prudent antimicrobial use. There is one area where you state, “The Public Health Agency of Canada and Health Canada have taken some steps to promote prudent antimicrobial use in humans.” Can you discuss what those steps are, please?